## Please add the following Claims 25-28:

25. (New) The vaccine of Claim 10, wherein said vaccine is protective against a challenge with said one or more *Clostridium botulinum* toxins.

26. (New) The vaccine of Claim 11, wherein said vaccine is protective against a challenge with said *Clostridium botulinum* type A toxin.

27. (New) The vaccine of Claim 10, wherein said portion of *Clostridium* botulinum type B toxin is selected from the group consisting of SEQ ID NO:44 and SEQ ID NO:46, and said portion of *Clostridium botulinum* type E toxin is selected from the group consisting of SEQ ID NO:54 and SEQ ID NO:56.

28. (New) The vaccine of Claim 11, wherein said portion of *Clostridium*botulinum type A toxin is selected from the group consisting of SEQ ID NO:26 and SEQ ID
NO:36.

## REMARKS

## 1. Status of the Application

Claims 1-24 are pending in the application.

Claims 1-9 and 15-24 have been cancelled in response to a restriction requirement, without traverse, and without prejudice to their renewal in another application.

Claim 10 has been amended to more clearly describe Applicant's invention. Support for this amendment is found in the specification which teaches that the "vaccine may be a monovalent vaccine (i.e., containing only a toxin B fusion protein or a toxin E fusion protein), a bivalent vaccine (i.e., containing both a toxin B fusion protein and a toxin E fusion protein) or a trivalent or higher valency vaccine."

Claims 25-28 have been added to more clearly describe Applicant's invention.

Specification, page 26, lines 24-27.